Sonoma Pharmaceuticals, Inc. announced its financial results for its first fiscal quarter ended June 30, 2025, on August 7, 2025. The company reported an 18% increase in total revenues compared to the same period last year.
U.S. revenue demonstrated particularly strong growth, increasing by 57% compared to the prior year's first quarter. This highlights successful market penetration and commercial execution in the domestic market.
The net loss per share also saw a significant improvement, decreasing by 43% compared to the same period last year. These results indicate continued substantial revenue growth and improved financial performance as the company begins its fiscal year 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.